ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: GlobeNewswire
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023 Successfully completed LOTIS-7 dose escalation and initiated expansion in 2L+ DLBCL Initial MZL IIT Phase 2 data from 15 patients showed 13 patients with CR and 1 patient with PR; encouraging data compared to current treatments in area with high unmet medical need Research event featured next-generation ADC platform and the Company’s most advanced ADC targets including promising preclinical data in NaPi2b, Claudin-6, PSMA and ASCT2 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the first quarter ended March 31, 2024, and provided business updates. “During the first quarter of 2024, we were pleased to see continued progress from our corporate and ca
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQGlobeNewswire
- Antibody Drug Conjugates (ADC) Size, Share & Trends Analysis Report 2024: Global Market to Surpass $24 Billion by 2030, Driven by a Strong Product Pipeline & Rising Incidence and Prevalence Of Cancer [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics SA (NYSE:ADCT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceGlobeNewswire
ADCT
Earnings
- 5/6/24 - Beat
ADCT
Sec Filings
- 5/14/24 - Form 8-K
- 5/10/24 - Form 4
- 5/9/24 - Form 4
- ADCT's page on the SEC website